Literature DB >> 12883661

Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.

Sung-Chul Lim1, Sung-Yong Park, Nam-Yong Do.   

Abstract

The purpose of this study was to determine whether cyclooxygenase-2 (COX-2) was overexpressed in head and neck squamous cell carcinoma (HNSCC) in relation to vascular endothelial growth factor (VEGF) expression and lymph node metastasis. COX-2 has an important role in the promotion of carcinogenesis, tumor invasiveness and angiogenesis. VEGF is a proangiogenic factor that is up-regulated in various tumors. VEGF has been shown to interact with COX-derived prostaglandins in angiogenesis. To better understand the roles of these genes in HNSCC, we evaluated the immunohistochemical expression pattern of COX-2 and VEGF in relationship with histologic differentiation, clinical stage, and nodal status in 146 HNSCC. The COX-2/VEGF double immunofluorescein staining was evaluated with confocal scanning laser microscope. A positive expression was seen in 96% (140/146: 98 strong positive, 42 weakly positive) for COX-2 and in 98% (143/146: 63 strong positive, 80 weakly positive) for VEGF in HNSCC. A correlation was present in the positive expression of COX-2 with histologic differentiation, clinical stage, and nodal status. VEGF expression was also correlated with nodal status. A significant relation was observed between COX-2 and VEGF expressions. The simultaneous expression of COX-2 and VEGF was statistically significant (p<0.05). These results indicate that elevated COX-2 or VEGF expression is more common in HNSCC with poor prognostic characteristics. The present findings support the efforts to initiate clinical trials on the efficacy of COX-2 inhibitors in adjuvant treatment of HNSCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883661

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.

Authors:  Athanassios Argiris; Ashley Buchanan; Bruce Brockstein; Jill Kolesar; Musie Ghebremichael; Michael Pins; Kristine Hahn; Rita Axelrod; Arlene Forastiere
Journal:  Cancer       Date:  2009-10-01       Impact factor: 6.860

2.  Relation between proinflammatory mediators and epithelial-mesenchymal transition in head and neck squamous cell carcinoma.

Authors:  Geun-Woo Dong; Nam-Yong DO; Sung-Chul Lim
Journal:  Exp Ther Med       Date:  2010-07-21       Impact factor: 2.447

3.  Deletion of the FHL2 gene attenuating neovascularization after corneal injury.

Authors:  Pao-Hsien Chu; Lung-Kun Yeh; Hsin-Chiung Lin; Shih-Ming Jung; David Hui-Kang Ma; I-Jong Wang; Hsueh-Hua Wu; Tzu-Fang Shiu; Ju Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-15       Impact factor: 4.799

4.  Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells.

Authors:  Jianwu Hu; Caiyun Chen; Yuan Su; Jiao DU; Xin Qian; Yang Jin
Journal:  Exp Ther Med       Date:  2012-09-10       Impact factor: 2.447

5.  Correlation between vascular endothelial growth factor expression and presence of lymph node metastasis in advanced squamous cell carcinoma of the larynx.

Authors:  Rodrigo Gonzalez Bonhin; Vanessa Brito Campoy Rocha; Guilherme Machado de Carvalho; Alexandre Caixeta Guimarães; Agrício Nubiato Crespo; Carlos Takahiro Chone; Eliane M I Amstalden
Journal:  Braz J Otorhinolaryngol       Date:  2014-11-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.